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efﬁ cacy of VSL#3 (all doses) comparing to placebo and slightly more effective for 
VSL#3 (6 g/day) comparing to placebo with RR of 20.35 with a 95% CI of 6.16–
67.22 (P < 0.0001). Efﬁ cacy of antibiotics comparing to placebo showed a summary 
RR of 2.68 with a 95% CI of 0.4–17.99 and P = 0.3107 for clinical improvement in 
three trials. The summary RR for efﬁ cacy of ciproﬂ oxacin comparing to metronidazole 
was 0.68 with a 95% CI of 0.44–1.06 (P = 0.8913). CONCLUSIONS: In conclusion, 
alongside the beneﬁ t of probiotics and antibiotics in the management of pouchitis, 
effects of probiotics and antibiotics on pouchitis vary according to different mixtures 
of microorganisms strains in probiotics and different spectrums of antibiotics.
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OBJECTIVES: To evaluate the prevalence and incidence of hepatitis a in a managed 
care population, segmented by a range of characteristics including age, gender, geog-
raphy, and health insurance plan. METHODS: This was an observational retrospec-
tive cohort study utilizing medical and pharmacy claims data for January 1, 2005 
through December 31, 2008 from the Impact National Managed Care Database 
(Benchmark Database). The index date was deﬁ ned as the date of the ﬁ rst and only 
diagnostic claim for hepatitis a within the intake period. All prevalence results reported 
below are per 100,000 and incidence is presented as per person years. RESULTS: Out 
of a total of 94,985,124 subjects in the database, females and males were represented 
equally (51% and 49% respectively). The 45–64 year age group had the greatest 
percentage of subjects. The prevalence of hepatitis a among men and women were 
almost equal (9 and 8, respectively). The 45–54 years age group had the highest hepa-
titis a prevalence (4) followed by the 25–34, 35–44, and 55–64 age groups (3 for each 
group). The largest hepatitis a prevalence rate was from the northeast region (7) fol-
lowed by the south (6). In the 2005–2008 timeframe, hepatitis a prevalence was similar 
in each year (4). Incidence rates across age, region and speciﬁ c zip codes in person 
years were less than 1 person per year. The incidence was slightly higher in males. 
Among three digit zip codes, the zip codes “100” showed higher incidences each year 
with higher prevalence. CONCLUSIONS: In a large commercially insured US popula-
tion, we observed similar prevalence rates of hepatitis a for males and females. The 
disease was most prevalent in the 45–54 years age group. The northeast had the 
highest prevalence rate from 2005–2008. 
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OBJECTIVES: Cost-effectiveness analyses of new hepatitis C drugs have been used to 
select and approve drugs that should be ﬁ nanced by the public health care system. 
However there are still a huge amount of uncertainties within these studies. The fact 
of having pharmacoeconomic and budget impact data of these new pharmacological 
alternatives will help to select the most efﬁ cient alternative. With this, the objective is 
to perform a budget impact analysis (BIA) of the treatment with pegylated interferon 
(pegIFN), alfa-2a or alfa-2b, plus ribavirin in, economically active genotype I patients, 
aging from 30 to 59 years, with chronic hepatitis C (CHC). METHODS: An interac-
tive model has been designed from the inputs obtained from the medical literature. 
Both strategies have been considered as therapeutic equivalents, without signiﬁ cative 
difference in side effects, and as having the same price. RESULTS: The number of 
patients with CHC evaluated in the model has been of 355,611, 15.2% between 30 
and 39 years, 13% between 40 and 49 years and 9% between 50 and 59 years, 
mimicking the Brazilian population and with an average weight of 70.6 kg. The dura-
tion of treatment was 48 weeks, with virologic response measured in weeks 2.4,12.24 
and 48. a total of 91% and 99.8% of the patients receiving pegIFN alfa-2a or alfa-2b, 
respectively achieved sustained virological response at 72 weeks. Total cost was R$ 
4,012,531,131.29 and R$3,752,238,973.99 for the treatment with pegIFN alfa-2a + 
RIB and pegIFN alfa-2b + RIB, respectively. CONCLUSIONS: Although cost-effec-
tiveness analysis appears to be favorable to pegIFN alfa-2a + RIB, a BIA seems to 
favour pegIFN alfa-2b + RIB due to its better predictability in the 12nd week of treat-
ment. In this case, the treatment with pegIFN alfa-2b + RIB (in comparison with 
pegIFN alfa-2a + RIB) is an efﬁ cient strategy.
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OBJECTIVES: MR Elastography (MRE) is a non-invasive test under clinical trial 
evaluation for effectiveness in helping diagnose liver ﬁ brosis. This study estimated the 
accuracy needed for MRE to be cost-neutral from a US payer’s perspective. 
METHODS: We constructed a decision-analytic model comparing diagnostic costs 
under two scenarios for patients with suspected liver ﬁ brosis: 1) biopsy, or 2) MRE 
followed by biopsy when the MRE test was positive. We conducted a targeted litera-
ture review and consulted with a leading hepatologist and pathologist to identify the 
appropriate procedure codes associated with liver biopsy; we assumed MRE would 
be reimbursed using CPT-4 code 74,181 (magnetic resonance (eg., proton) imaging, 
abdomen; without contrast material(s)). We assigned the appropriate allowable 
charges to the identiﬁ ed procedure codes using the 2010 Medicare Physician Fee 
Schedule. Finally, we assumed negative predictive values (NPV) of 0.8, 0.9 and 0.95, 
and that patients with a false-negative MRE ultimately received a biopsy. RESULTS: 
The cost of a liver biopsy was $1424 (ultrasound $164, surgical $881, pathology 
$347, laboratory $32) and the cost of an MRE (without contrast) was $946 (hospital 
setting) or $666 (non-hospital setting). In a hospital setting, MRE is potentially cost 
saving if the test-negative rate is greater than 83%, 74% and 70% for NPVs of 0.8, 
0.9 and 0.95, respectively. In a non-hospital setting, MRE can reduce diagnostic costs 
when more than 58%, 52% and 49% or patients have negative MRE results for the 
corresponding NPV values. CONCLUSIONS: The cost of liver biopsy is substantial 
as compared to MRE. MRE offers the potential of reducing the cost of diagnosing 
liver ﬁ brosis by avoiding unnecessary biopsies. Cost saving potential increases with 
MRE’s negative predictive value and negative test rate.
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OBJECTIVES: To analyze the use of health care resources and the associated costs in 
patients with opioid induced constipation (OIC). METHODS: An observational, 
retrospective, multicenter study was carried out in Spanish National Health System 
hospitals. All patients were free of constipation at baseline and received opioids for 
at least 2 months. In order to determine patient resource utilization, a review of the 
patient records and patient-interviews were performed to all patients diagnosed with 
OIC. Patients were evaluated depending on response to oral treatment for OIC. The 
observation period was 2 months. The unit costs were obtained from Spanish data-
bases (c 2009). RESULTS: A total of 744 patients were included. Patients had a mean 
(SD) age of 64.2 (13.4) and 48% were male. During the study period, 46.6% of the 
patients developed OIC. Most of these were treated ﬁ rst with oral laxatives exclusively 
(67.7%), 63.8% responded to the treatment and 36.2% did not. Of the total number 
of patients with OIC, 61.5% required a visit to health care services. Forty-four patients 
required a visit to the Emergency Room (ER) and 26 were hospitalized with a median 
length of stay of 3 days. Overall mean total cost (SD) of constipation management 
was c271.08 (c621.22). Resource utilization in responders to oral laxatives was sta-
tistically signiﬁ cant lower than in non-responders. a higher percentage of non-respond-
ers required health care visits, ER visits, and hospitalizations (P < 0.001). The mean 
cost (SD) for each responder was c115 (c230) compared to c442 (c810) for each 
non-responder (P < 0.001). CONCLUSIONS: OIC increases health care resource 
utilization particularly in patients with a poor response to oral laxatives. The economic 
burden of OIC was 3.8 times higher in non-responders than in responders.
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OBJECTIVES: To determine the impact of rotavirus (RV) disease as a secondary 
diagnosis on hospital length of stay (LOS) and cost for children under ﬁ ve years of 
age in England. METHODS: The study was based on Hospital Episodes Statistics for 
England 2001–2007 using a matched cohort design. Admissions with a secondary 
diagnosis of RV were extracted and matched by age, year of admission and, where 
relevant, therapeutic procedure, to other admissions from HES with the same primary 
diagnosis. Primary admissions were classiﬁ ed as potentially related or unrelated to 
RV. LOS was compared using the paired Wilcoxon test. RESULTS: Of 2126 admis-
sions with a secondary diagnosis of RV, 707 (33.3%) had no other secondary diag-
noses. Of these, 385 admissions were matched for primary diagnosis to controls. 
Median LOS for admissions was 2.0 days (Inter-Quartile Range [IQR] 1.0–4.0), mean 
(sd) 3.2 (4.1) compared with median 1.0 (IQR 0.0–1.5), mean 1.4 (sd 3.5) for control 
admissions (p-value < 0.001). Median cost/admission was £771 (IQR £604–£1090), 
mean cost was £1105 (sd £1064) compared with median £650 (IQR £564–£1090), 
£902 (sd 1004) (p-value < 0.001). a total of254/385 admissions were deﬁ ned as 
unrelated to RV. For these admissions, median LOS was 2.0 days (IQR 1.0–4.25), 
mean 3.7 (sd 4.5) compared with median 1.0 (IQR 0.0–2.0), mean 1.6 (sd 4.0) for 
control admissions (p-value < 0.001). Median cost/admission was £918 (IQR £564–
£1090), mean £1132, (sd £1132) compared with median £771 (IQR £564–£1090), 
mean £980 (sd £1187), (p-value < 0.001). CONCLUSIONS: As a secondary diagnosis 
in HES, RV has a signiﬁ cant incremental impact on LOS and cost. Variations in testing 
and reporting of RV mean that HES data may signiﬁ cantly under represent the overall 
burden of RV disease. This implies that standard modelling methodologies may 
underestimate the true burden of RV disease in the context of health care acquired 
infection.
